Search Results
Your search for Staff,Staff matches 6765 pages
Showing 51 - 100
Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease
Rachel E. Rau, MD, of Seattle Children’s Hospital, and Sumit Gupta, MD, PhD, of the Hospital for Sick Children in Toronto, review results from Children’s Oncology Group Study AALL1731, which assessed the addition of blinatumomab to chemotherapy in newly diagnosed childhood standard-risk B-cell...
Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL
Nitin Jain, MD, of The University of Texas MD Anderson Cancer Center, Houston, discusses the results of a recent trial (Abstract 1011) evaluating the time-limited, combination therapy of the noncovalent Bruton’s tyrosine kinase inhibitor pirtobrutinib with the BCL2 inhibitor venetoclax and the CD20 ...
Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia
Danielle Wolfe Cohen, MD, of the William L. Carroll Laboratory at New York University Grossman School of Medicine, describes data illuminating the role of an inflammatory phenotype in driving clonal evolution in B-cell acute lymphoblastic leukemia. The new findings may indicate promising avenues...
Anne Sophie Michallet, MD, PhD, on MRD-Guided vs Standard Combination Therapy for Select Untreated Patients With CLL
Anne Sophie Michallet, MD, PhD, of Centre Léon Bérard Hospital, Lyon, France, discusses the final results of the phase II ERADIC trial (Abstract 584), which compared measurable residual disease (MRD)-guided therapy with ibrutinib and venetoclax with a standard combination regimen in patients with...
Common Bacterial Toxin May Speed Up Colorectal Cancer Metastasis
A bacterial toxin may accelerate the spread of colorectal cancer to other parts of the body, according to a recent study published by He et al in Cell Host & Microbiome. The findings could pave the way for novel tools to detect metastatic colorectal cancer early and determine which patients may ...
Loncastuximab Tesirine May Improve Outcomes in High-Risk Follicular Lymphoma, Marginal Zone Lymphoma
The antibody loncastuximab tesirine may offer a benefit in patients with high-risk follicular lymphoma and marginal zone lymphoma, according to the findings of two clinical trials presented by Alderuccio et al and Lossos et al at the 2024 American Society of Hematology (ASH) Annual Meeting &...
Rilzabrutinib Found Safe and Effective for Refractory Immune Thrombocytopenia
The experimental drug rilzabrutinib was well tolerated and generated an increase in platelet counts among some adults with immune thrombocytopenia (ITP) who had not experienced lasting improvements with other available ITP treatments, according to the results of a phase III trial. These findings...
Preclinical Findings Show Ketogenic Diet Enhances CAR T-Cell Function, Improves Tumor Control
Findings from a series of studies conducted in mice, human tissues, and healthy volunteers suggest that a ketogenic diet may enhance the effectiveness of chimeric antigen receptor (CAR) T-cell therapy. The results point to β-hydroxybutyrate (BHB), a substance produced when a ketogenic diet is...
Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-duration acalabrutinib/venetoclax—with or without obinutuzumab—with investigator’s choice of...
Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)
Maayan Levy, PhD, and Marco Ruella, MD, of the University of Pennsylvania, Perelman School of Medicine, discuss findings on whether ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models. The results of this study will be translated...
Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD
Nikolaos Katsivelos, MD, and John Levine, MD, MS, of Icahn School of Medicine at Mount Sinai report on an investigation into the potential for serial monitoring of graft-versus-host disease (GVHD) symptom severity and MAGIC algorithm probabilities in patients with clinical and biomarker-defined...
Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial
Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, Boston, discusses the findings from the prespecified interim analysis of the phase III AMPLIFY trial (Abstract 1009), which compared fixed-duration acalabrutinib/venetoclax—with or without obinutuzumab—with investigator’s choice of...
Award Recipients Announced for the 2024 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will honor two researchers for their significant contributions to breast cancer research during the 2024 SABCS. 2024 AACR Distinguished Lectureship in Breast Cancer Research ...
Metformin May Impact Immunotherapy in NSCLC
Metformin may strengthen the effects of immunotherapy and improve recurrence-free survival in patients with lung cancer with overweight or obesity, according to a recently published article in the Journal of the National Cancer Institute.1 The investigators looked at data from two groups of...
NCCN Joins International Cancer Organizations During Oncology Event in China
The National Comprehensive Cancer Network (NCCN) took part in the 2024 International Congress of the Asian Oncology Society and the 2024 Chinese Congress on Holistic Integrative Oncology. This event highlighted international collaborations to improve cancer therapy and outcomes across China and...
Roswell Park Announces Center’s First Physician-in-Chief
Candace S. Johnson, PhD, President and Chief Executive Officer of Roswell Park Comprehensive Cancer Center, recently announced the appointment of Michael Wong, MD, PhD, FRPC, as the cancer center’s first Physician-in-Chief. Dr. Wong is a medical oncologist and skin cancer expert, who joined...
Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer
A novel immunotherapy may offer a new option for patients with bladder cancer who no longer respond to bacillus Calmette-Guérin (BCG), according to a study presented on December 5 at the 2024 Society of Urologic Oncology Annual Meeting in Dallas. The therapy, cretostimogene grenadenorepvec, is an...
Understanding How Stigma and Incorrect Physician Assumptions About LGBTQ+ Patients’ Needs Contribute to Medical Mistrust
Over the past decade, ASCO has focused its resources on advancing health equity for sexual and gender minority (SGM) individuals with cancer. In 2017, the Society published a position statement “Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations,” which...
Impact of Prevention and Screening on Mortality From Five Common Cancers
Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published by Goddard et al in JAMA...
Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer
A novel cell-based immunotherapy may enhance treatment responses and reduce the need for conventional chemotherapy and its associated toxicities in patients with breast cancer, according to a recent study published by Han et al in JAMA Oncology. Study Methods and Results In the phase I clinical...
Self-Pay, AI-Based Program May Help Boost Mammogram Findings
A self-pay, artificial intelligence (AI)-enhanced breast cancer screening program could help improve breast cancer detection rates, according to new findings presented by Sorensen et al at the Radiological Society of North America (RSNA) 2024 Annual Meeting (Abstract R5B-SPBR-4). Background Despite ...
Accelerated Approval Granted to Zanidatamab-hrii for HER2-Positive Biliary Tract Cancer
The U.S. Food and Drug Administration (FDA) recently granted accelerated approval to zanidatamab-hrii (Ziihera), a bispecific HER2-directed antibody, for previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test. The FDA also...
Oral Liquid Imatinib Approved by the FDA in Leukemia
The U.S. Food and Drug Administration (FDA) recently has approved an oral solution of the tyrosine kinase inhibitor, imatinib mesylate, called Imkeldi, to treat certain types of leukemia and other cancers. The new solution is an advanced liquid formulation of imatinib designed to provide dosing...
Cetuximab vs Durvalumab in Treatment of Head and Neck Cancers
Durvalumab, an immune checkpoint inhibitor, has shown activity in treating a wide range of cancers and has been proposed as a potentially safer and more effective option than cetuximab, according to Loren K. Mell, MD, Professor and Vice Chair of Clinical and Translational Research at University of ...
Deciphering the Impact of the 2024 Election on Cancer Care
Two weeks after the 2024 election, the Presidency and 119th Congress are coming into focus, with nearly all races called. Republican Donald Trump was elected President, and Republicans regained control of the U.S. Senate (53–47) and maintained control in the House of Representatives (218–212 at...
FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer
On December 4, 2024, the U.S. Food and Drug Administration approved durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer (SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Efficacy was evaluated in ADRIATIC...
IMF Welcomes Newly Elected Board of Directors Members
The International Myeloma Foundation (IMF) welcomes four of its newest members to the IMF Board of Directors: Director of Strategic Growth at Raanes & Oliver Capital Advisors, Kent Oliver; Managing Partner of Global Commercialization Strategy and Solutions at ZS Associates, Maria Whitman;...
Updated Findings in Preventive Breast Cancer Vaccine Study
Researchers from Cleveland Clinic recently presented updated findings from a novel study of a vaccine aimed at preventing triple-negative breast cancer. The findings were presented at the Society for Immunotherapy of Cancer Annual Meeting.1 According to researchers, including principal...
ASH Announces Recipients of 2024 ASH Advocacy Awards
The American Society of Hematology (ASH) honored Rep. Michael Burgess, MD (R-TX) and Centers for Disease Control and Prevention (CDC) health scientist Mary Hulihan, DrPH, for their leadership on issues of importance to hematology research and practice at the 2024 ASH Annual Meeting &...
FDA Grants Approval to New Bispecific Antibody for NSCLC and Pancreatic Adenocarcinoma
On December 4, 2024, the U.S. Food and Drug Administration granted accelerated approval to the HER2 × HER3 bispecific antibody zenocutuzumab-zbco (Bizengri) for adults with the following types of lung and pancreatic cancers: advanced, unresectable, or metastatic non–small cell lung cancer (NSCLC)...
Potential Cancer Vaccine Target Uncovered in E coli Bacteria
Targeting certain bacterial strains linked to cancer with treatments or vaccines may help to reduce the risk of colorectal cancer, urothelial carcinoma, and prostate cancer, according to a novel study published by Mäklin et al in The Lancet Microbiome. Background The bacterium Escherichia coli is...
Prior Authorization Delays May Lead to Severe Consequences for Patients With Cancer
A recent nationwide survey has confirmed that prior authorization may cause treatment delays, abandoned treatments, hospitalizations, and deaths among patients with cancer, according to an executive summary published by the American Society for Radiation Oncology (ASTRO). The findings may reinforce ...
Temozolomide Plus Radiotherapy for Low-Grade Gliomas
Based on the phase III E3F05 trial, conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), the combination of radiation therapy and temozolomide appeared to be more effective than radiotherapy alone in the treatment of low-grade gliomas. The trial followed 172 patients for more than 10...
Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma
Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-200) and the PD-1 inhibitor pembrolizumab as first-line therapy for human papillomavirus type 16...
Study Highlights From MD Anderson Researchers
Here are some highlights of clinical trials presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center. They include breakthroughs in cancer care, updates in clinical research, and efforts in cancer...
Study Evaluating Lung Cancer Screening Program Receives Margulis Award for Scientific Excellence
The 2024 Alexander R. Margulis Award for Scientific Excellence honored the authors of a 20-year follow-up study on the International Early Lung Cancer Action Program (I-ELCAP). The Margulis Award was presented recently during the 2024 Radiological Society of North America (RSNA) Scientific Assembly ...
Impact of Menopausal Status on Long-Term Benefit From Antihormonal Treatment in Women With Breast Cancer
New research has shown that postmenopausal women with low-risk tumors have a long-term benefit for at least 20 years, whereas the benefit was more short-term for younger women with similar tumor characteristics who had not yet gone through menopause. The results were reported in the Journal of the ...
Regional, Racial, Economic Disparities in Air Pollution–Related Cancer Risk May Be Improving but Still Persist
Investigators report they have uncovered patterns in the risk of cancer associated with lifetime exposure to air pollution and how this risk may have changed over time, in a recent study published by Hurbain et al in Environmental Science & Technology. The findings could build on the scientific ...
Challenges, Potential of Mesenchymal Stem Cells in Cancer Immunotherapy
Investigators have assessed the potential role of mesenchymal stem cells in cancer treatment in a new review published by Minev et al in Oncotarget. Study Overview and Implications The investigators found that mesenchymal stem cells can naturally target tumors and deliver therapeutic agents...
Obecabtagene Autoleucel in Adults With B-Cell ALL
A second-generation chimeric antigen receptor (CAR) T-cell therapy may offer a new option for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), an aggressive blood cancer with few treatment options. Results from the phase Ib/II FELIX trial, published by Roddie et al in ...
Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer
Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a...
Poor Diets May Increase Risk of Gastrointestinal Cancer
New research may expand on existing evidence that a healthy diet may protect against gastrointestinal cancers and improve disease outcomes, according to a recent study published by Abebe et al in the European Journal of Nutrition. Background Gastrointestinal cancers including esophageal, gastric,...
Lung Cancer CT Screening May Help to Detect Coronary Artery Disease
Lung cancer screening with low-dose chest computed tomography (CT) may be capable of identifying coronary artery calcium in patients without cardiac symptoms, according to a recent study published by Caires et al in the Canadian Medical Association Journal. Background Lung cancer is currently one...
Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC
Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry (UPLC-MS/MS) method for comparing the pharmacokinetic properties of three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and their major metabolites in mouse...
Study May Illuminate Cause of Common Checkpoint Inhibitor Adverse Effect
Researchers may have uncovered the factors contributing to an increased susceptibility to common infections among patients with cancer receiving checkpoint inhibitors, according to a recent study published by Ogishi et al in Immunity. The findings may provide new insights into immune responses and...
At-Home Testing Kits, Coordinated Outreach May Improve Colorectal Cancer Screening Rates
Researchers have demonstrated that a targeted intervention may increase screening rates in patients who do not adhere to current colorectal cancer screening recommendations, according to a recent study published by Reuland et al in JAMA Network Open. Background Colorectal cancer screening is often...
Peer Support Intervention May Help Improve Psychological Outcomes Among Patients With Cancer in Low-Resource Settings
Researchers have found that the cancer peer support program Stronger Together may provide critical social support to patients with cancer, particularly in low-resource settings in low- and middle-income countries, according to a recent study published by Le et al in JCO Global Oncology. Background...
FDA Approves Oral Liquid Imatinib to Treat Patients With Leukemia and Other Cancer Types
The U.S. Food and Drug Administration (FDA) announced the approval of imatinib (Imkeldi) oral solution, the first oral liquid formulation of the drug to treat certain types of leukemias and other cancers. Background In 2024, an estimated 9,280 patients will be diagnosed with chronic myeloid...
Adding Temozolomide to Radiation Therapy May Improve Survival in Adults With Low-Grade Gliomas
Both radiation and temozolomide may have meaningful single-modality antitumor activity against slow-growing, low-grade gliomas, according to recent findings presented by Schiff et al at the 2024 Society for Neuro-Oncology Annual Meeting (Abstract LTBK-07) and simultaneously published in...
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
The studies summarized below were reported online over the past month in The ASCO Post, generating a high number of visitors. For comprehensive reviews of these studies and more, visit ASCOPost.com. Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer In the phase...
